Wang Haitao, Zheng Changlin, Wang Peisong
Department of Critical Care Medicine, The First Hospital of Jilin University, Changchun, China.
Department of Otorhinolaryngology Head and Neck Surgery, Lequn Branch, The First Hospital of Jilin University, Changchun, China.
Sci Rep. 2025 Feb 25;15(1):6692. doi: 10.1038/s41598-025-91221-7.
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterised by lipid deposition in liver cells. The global prevalence of NAFLD has significantly increased from 8.2% in 1990 to 30.2% in 2023, establishing it as a growing public health concern. In recent years, the name NAFLD has been replaced by metabolic dysfunction-associated fatty liver disease (MASLD). Numerous observational studies have investigated the potential association between hypothyroidism and MASLD; however, the findings remain inconsistent. In this context, a systematic analysis was conducted to examine the relationship between hypothyroidism and MASLD using data from a large cohort within the UK Biobank. Utilising prospective data from the UK Biobank, a Cox proportional hazards model supplemented with multiple sensitivity analyses was applied to investigate the association between the incidence of hypothyroidism and the onset of MASLD. In addition, stratified analyses and prognostic assessments were performed to assess potential effect modifiers. To explore the underlying mechanisms, mediation analyses were conducted, along with restricted cubic spline regression, to examine potential non-linear relationships and mediation effects within this association. The study found that after fully adjusting for multiple covariates, the risk of MASLD in hypothyroidism patients was 1.711 times that of non-hypothyroidism patients (95% CI 1.560-1.877, P < 0.001). Both subtypes of hypothyroidism, namely non-surgical related hypothyroidism (NSRH) and surgical related hypothyroidism (SRH), were associated with a markedly elevated risk of MASLD onset. For NSRH, the risk is increased by 1.710 times (95% CI 1.557-1.878, P < 0.001), and for SRH, the risk is increased by 1.763 times (95% CI 1.344-2.313, P < 0.001). Stratified analysis revealed an interaction effect between gender and BMI in relation to the risk of MASLD among individuals with NSRH. Mediation analysis revealed the critical role of specific biomarkers in elucidating the relationship between hypothyroidism and MASLD. Notably, red cell distribution width, C-reactive protein, HbA1c, and total protein were identified as significant mediators in this association. Patients with hypothyroidism exhibit a significantly increased risk of developing MASLD, with inflammatory and metabolic markers playing a mediating role in this association. These findings suggest that individuals with hypothyroidism, particularly those with elevated levels of inflammatory markers, may be at heightened risk for MASLD. As such, enhanced clinical monitoring of liver function in these patients is recommended to facilitate early detection and intervention.
非酒精性脂肪性肝病(NAFLD)是一种以肝细胞脂质沉积为特征的慢性肝病。NAFLD的全球患病率已从1990年的8.2%显著增至2023年的30.2%,这使其成为一个日益受到关注的公共卫生问题。近年来,NAFLD这一名称已被代谢功能障碍相关脂肪性肝病(MASLD)所取代。众多观察性研究探讨了甲状腺功能减退与MASLD之间的潜在关联;然而,研究结果仍不一致。在此背景下,利用英国生物银行中一个大型队列的数据进行了一项系统分析,以研究甲状腺功能减退与MASLD之间的关系。利用英国生物银行的前瞻性数据,应用Cox比例风险模型并辅以多项敏感性分析,来研究甲状腺功能减退的发生率与MASLD发病之间的关联。此外,还进行了分层分析和预后评估,以评估潜在的效应修饰因素。为探究潜在机制,进行了中介分析以及受限立方样条回归分析,以检验该关联中潜在的非线性关系和中介效应。研究发现,在对多个协变量进行充分调整后,甲状腺功能减退患者发生MASLD的风险是非甲状腺功能减退患者的1.711倍(95%置信区间1.560 - 1.877,P < 0.001)。甲状腺功能减退的两种亚型,即非手术相关甲状腺功能减退(NSRH)和手术相关甲状腺功能减退(SRH),均与MASLD发病风险显著升高相关。对于NSRH,风险增加1.710倍(95%置信区间1.557 - 1.878,P < 0.001),对于SRH,风险增加1.763倍(95%置信区间1.344 - 2.313,P < 0.001)。分层分析显示,在NSRH患者中,性别与BMI之间存在与MASLD风险相关的交互作用。中介分析揭示了特定生物标志物在阐明甲状腺功能减退与MASLD之间关系中的关键作用。值得注意的是,红细胞分布宽度、C反应蛋白、糖化血红蛋白和总蛋白被确定为该关联中的重要中介因素。甲状腺功能减退患者发生MASLD的风险显著增加,炎症和代谢标志物在该关联中起中介作用。这些发现表明,甲状腺功能减退患者,尤其是炎症标志物水平升高的患者,可能发生MASLD的风险更高。因此,建议加强对这些患者肝功能的临床监测,以便早期发现和干预。